Home>Topics>Companies>Orexigen Therapeutics

Orexigen Therapeutics

  1. All
  2. Commentary
  3. Headlines
  1. The Anti-Obesity Space Is Not As Simple As Some Think

    Headlines

    Fri, 20 Jun 2014

    think of Vivus ( VVUS ), Arena Pharmaceuticals ( ARNA ), and Orexigen ( OREX ). These three companies have been the center of attention ..... two already have products on the market, and the third, Orexigen , is likely to see its anti-obesity drug approved this Fall

  2. What Will It Take For Arena Stock To Rise?

    Headlines

    Mon, 16 Jun 2014

    the equity to appreciate. The frustrations seem to have come to a head following the combination of a delay for competitor Orexigen combined with a 23% uptick in week over week prescription sales numbers last week. Investors seem to feel that these two

  3. Arena's Belviq Sales Do More Than Recover

    Headlines

    Fri, 13 Jun 2014

    investors in Arena Pharmaceuticals ( ARNA ). The sales of Belviq took an anticipated dip with last week's numbers, competitor Orexigen ( OREX ) saw its application for approval of Contrave delayed until September, Arena's CEO spoke on CNBC, and this weeks numbers

  4. Orexigen Therapeutics ( OREX ) Receives Three Month Extension of FDA NB32 Review (Transcript)

    Headlines

    Wed, 11 Jun 2014

    Orexigen Therapeutics ( OREX ) Orexigen Receives Three Month Extension of FDA NB32 Review June 11, 2014 ..... Mathew Andrews - Wells Fargo Presentation Operator Welcome to the Orexigen Conference Call. My name is Joan and I will be your operator

  5. UPDATE 2-FDA delays decision on Orexigen's obesity drug by 3 months

    Headlines

    Wed, 11 Jun 2014

    June 11 (Reuters) - Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed a decision on the marketing application for its obesity drug, contrave, by three months, sending the...

  6. FDA Delays Decision On Orexigen Anti-Obesity Drug - What This Means To The Stock

    Headlines

    Wed, 11 Jun 2014

    By Spencer Osborne : Orexigen ( OREX ) announced this morning that an FDA decision on approval of the ..... approval were in the equity for the trade. Two months ago I labeled Orexigen as a buying opportunity with the stock near $5. At that point

  7. Orexigen PDUFA date extended three months

    Headlines

    Wed, 11 Jun 2014

    The FDA extends its review of Orexigen Therapeutics ' ( OREX ) resubmitted NDA for NB32 , the company's weight loss ..... agreement on the remaining post-marketing obligation." OREX shares are down 11% premarket on robust volume. Post

  8. FDA delays decision on Orexigen's obesity drug by three months

    Headlines

    Wed, 11 Jun 2014

    June 11 (Reuters) - Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed its decision on the marketing application of its obesity drug, contrave, by three months, sending its...

  9. Orexigen Investors Hope For FDA Approval

    Headlines

    Tue, 10 Jun 2014

    By Spencer Osborne : Orexigen ( OREX ) is just a day away from receiving ..... VVUS ). Leading up to this date, Orexigen has seen a nice run in its stock ..... around $7.00. At this point, Orexigen longs may not appreciate what I have

  10. Orexigen Could Be A Double-Edged Sword For Arena

    Headlines

    Mon, 9 Jun 2014

    dots for you. This will be one of those occasions. This Wednesday, the FDA will likely make a determination about the Orexigen ( OREX ) entry (Contrave) into the anti-obesity space. This is both good news and bad news for investors in Arena Pharmaceuticals

« Prev1234Next »
Content Partners